Longevity

SS-31 Dosing & Reconstitution Calculator

Mitochondria-targeted peptide (Elamipretide) protecting against oxidative stress.

TL;DR — SS-31 is a longevity peptide with a typical starting dose of 10 mg. For a 50 mg vial, add 2 mL bacteriostatic water to yield 25 mg/mL.
10 mg
Start Dose
50 mg
Vial
2 mL
BAC Water
25
mg/mL
Compare Similar
Track SS-31 in Protocol Tracker
Frequently Asked
How do I reconstitute SS-31?
Add 2 mL of bacteriostatic water to a 50 mg vial, injecting slowly down the inside wall. Swirl gently; never shake. This yields a concentration of 25 mg/mL.
What is the recommended dose of SS-31?
A typical research dose is 10 mg. Consult the ASCEND calculator for your specific vial concentration and draw volume.
How many doses are in a SS-31 vial?
A 50 mg vial reconstituted with 2 mL BAC water yields approximately 5 doses at 10 mg each.
Peptide Intelligence
What is SS-31 and how does it work?
SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) is a mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane by binding cardiolipin. It prevents cytochrome c release, reduces ROS production, and restores mitochondrial cristae architecture in damaged cells.
What is the half-life of SS-31?
SS-31 has a plasma half-life of approximately 2–3 hours after subcutaneous injection, but its tissue half-life in mitochondria-rich tissues such as heart, kidney, and brain may be significantly longer. Daily subcutaneous injections are used in most research protocols.
What diseases is SS-31 being clinically researched for?
Clinical trials have studied SS-31/Elamipretide for Barth syndrome, heart failure, dry age-related macular degeneration, primary mitochondrial myopathy, and renal ischemia-reperfusion injury. Multiple Phase 2 trials have demonstrated safety and preliminary efficacy signals.
Recommended Next Step
Mitochondrial Stack
MOTS-C complements SS-31 with nuclear gene regulation and metabolic homeostasis alongside SS-31's direct mitochondrial membrane protection.
Open MOTS-C Calculator →
Also Explore
Primary Sources
Elamipretide Review (Front Physiol 2020) ClinicalTrials NCT04063332
Data last reviewed 2026-04-19 · Methodology →
Cite This Calculator